Drugs / BNT166a
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05988203 | Sep 2023 → Aug 2025 | monkeypox | BioNTech SE | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07379580 | Feb 2026 → Jun 2027 expected | human infection by orthopoxvirus, monkeypox, smallpox | BioNTech SE | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BNT166a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07379580 ↗ |
| Modality | Messenger RNA (mRNA) | “The quadrivalent mRNA vaccine candidate BNT166a encoding MPXV antigens A35, B6, M1, and H3 was selected for clinical development” PMID 42235570 ↗ Jun 2026 |
| Route | Intramuscular | “administered as intramuscular injection” NCT05988203 ↗ |